
TSE:EXE
This summary was created by AI, based on 4 opinions in the last 12 months.
Extendicare Inc (EXE-T) occupies a unique position within the healthcare landscape, particularly benefiting from demographic trends favoring long-term care and home healthcare services. Experts highlight its asset-light approach in real estate and the increasing governmental support for home healthcare, suggesting potential growth opportunities. While there is optimism about its earnings and margin management, some analysts express caution due to market saturation and competitive pressures from well-financed private equity firms, which may already be factored into the stock price. The company's fair dividend policy, which distributes about half of its funds from operations (FFO), adds to its attractiveness, but uncertainty about growth prospects has led some experts to explore alternative investments. Overall, Extendicare's stability in long-term care and the promising future of its home healthcare segment form the crux of its evaluation.
This space is now all the rage. A tough business. We are underbuilt, and the demographic wave is coming through. But all that's already in the share price. Be careful, especially with stocks that go parabolic on the chart. There are some very-well-financed private equity players that are hiding supply.
He owns SIS instead.
Doesn't follow it closely. Does, however, follow CSH.UN.
Very reasonably valued at 13x when you look at price to FFO. Similar market to CSH.UN, but EXE is a corporation and that makes it unique. (REITs have to pay out more, or there's a punitive tax.) Pays out roughly half of its FFO. Likes the business model. Bouncing back from pandemic. Doesn't own due to growth outlook.
Both LTC and home healthcare. Long waitlist for LTC beds, so no risk on earnings side. Very good at managing margins.
Home healthcare is what's growing -- asset light, so dividend won't be as enticing as with other names. Demographics are on its side, but it's hard for him to assign a NAV to it. He'd focus more on names like CSH.UN and SIA.
Focused on LTC in Ontario, also a home healthcare business just in Ontario (which forms 50% of the business). No longer in retirement homes. If you own it, you've done well; continue to hold and collect the yield now south of 4%. If you have strong view of the home healthcare business, you could dip in at a better entry point.
EXE operates long-term care facilities which require a lot of capital, while CSH is more senior homes. CSH has been divesting lower-return investments to become more of a pure-play. You can charge whatever rent in a market if there's no competition. The seniors' population keeps growing. CSH is paying down debt, which was high a few years ago. In CSH, the easy money has been made, though. It could be a keeper, or take profits.
How COVID will effect this industry, retirement homes? He owns Sienna instead. EXE is much more involved in government-funded LTCs. Along with Chartwell, these two companies are under government scrutiny, so they likely do a much better job than private LTCs. Good question how COVID will affect these homes: there may be increased costs to manage the LTCs, and he expects the government to do more oversight, particularly the incompetent LTCs. He prefers Sienna to EXE, because Sienna is a mix of LTCs and retirement homes, while Chartwell is mostly retirement homes, which has more upside but more competitive. Don't buy purely LTCs, like EXE.
Extendicare has a better chart than Chartwell. It has a head-and-shoulder chart movement. If you take into account the general market sell-off, investors need to be forgiving.
Extendicare Inc is a Canadian stock, trading under the symbol EXE.TO (previously EXE-T on Stockchase) on the Toronto Stock Exchange (EXE-CT). It is usually referred to as TSX:EXE or EXE.TO
In the last year, 4 stock analysts issued a Buy, Sell, or Hold rating on EXE.TO (previously EXE-T on Stockchase). 1 analyst recommended to BUY and 2 analysts recommended to SELL the stock. The latest stock analyst rating is BUY on WEAKNESS. Read the latest stock experts' ratings for Extendicare Inc.
Extendicare Inc was recommended as a Top Pick by Bruce Campbell (1) on 2019-10-29. Read the latest stock experts ratings for Extendicare Inc.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Extendicare Inc.
Extendicare Inc is followed by 172 investors on Stockchase and is a trending stock that is worth watching.
On 2026-06-26, Extendicare Inc (EXE.TO) stock closed at a price of $35.45.
Amazing chart. In prime position to take advantage of the demographic story. More of an asset-light play in real estate. Ontario government's increasing funding to home healthcare providers, and it's the largest player. Managing margins well.
High growth, still has legs to mid-high $30s.